de Wit, E., et al., SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol, 2016. 14(8): p. 523-34.
Lu, R., et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 2020. 395(10224): p. 565-574.
Zhou, P., et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020. 579(7798): p. 270-273.
Li, W., et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003. 426(6965): p. 450-4.
Kuba, K., et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med, 2005. 11(8): p. 875-9.
Hoffmann, M., et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020. 181(2):271-280
Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020. 395(10223): p. 497-506.
Cao, X., COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol, 2020. 20(5): p. 269-270.
Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020. 395(10223): p. 507-513.
Chen, X., et al., Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis, 2020.
Giamarellos-Bourboulis, E.J., et al., Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe, 2020. doi: 10.1016/j.chom.2020.04.009
McGonagle, D., et al., The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev, 2020: p. 102537.
Hirano, T. and M. Murakami, COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity, 2020. 52(5): p. 731-733.
Norelli, M., et al., Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med, 2018. 24(6): p. 739-748.
Giavridis, T., et al., CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med, 2018. 24(6): p. 731-738.
Neelapu, S.S., et al., Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol, 2018. 15(1): p. 47-62.
Xu, X., et al., Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A, 2020. 117(20):1097-10975
Luo, P., et al., Tocilizumab treatment in COVID-19: A single center experience. J Med Virol, 2020. doi: 10.1002/jmv.25801
Alattar, R., et al., Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol, 2020. doi: 10.1002/jmv.25964
Hirano, T., et al., Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature, 1986. 324(6092): p. 73-6.
Hirano, T., Interleukin 6 and its receptor: ten years later. Int Rev Immunol, 1998. 16(3-4): p. 249-84.
Hirano, T., Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir. Proc Jpn Acad Ser B Phys Biol Sci, 2010. 86(7): p. 717-30.
Ogura, H., et al., Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity, 2008. 29(4): p. 628-36.
Murakami, M., et al., Disease-association analysis of an inflammation-related feedback loop. Cell Rep, 2013. 3(3): p. 946-59.
Murakami, M., D. Kamimura, and T. Hirano, Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. Immunity, 2019. 50(4): p. 812-831.
Nishimoto, N., et al., Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood, 2005. 106(8): p. 2627-32.
Maini, R., et al., Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis & Rheumatism, 2006. 54(9): p. 2817-2829.
Yamamoto, M., et al., Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. Antimicrob Agents Chemother, 2016. 60(11): p. 6532-6539.
Kopf, M., et al., Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature, 1994. 368(6469): p. 339-42.
Ladel, C.H., et al., Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun, 1997. 65(11): p. 4843-9.
Dienz, O., et al., Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol, 2012. 5(3): p. 258-66.
Sheahan, T., et al., MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog, 2008. 4(12): p. e1000240.
Sun, B., et al., Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect, 2020. 9(1): p. 940-948.
Sato, J. If I were North Amerian/West European/Australian, I would take BCG vaccination now against the novel coronavirus pandemic. https://www.jsatonotes.com/2020/03/if-i-were-north-americaneuropeanaustral.html
Netea, G. N, et al, Trained Immunity: a Tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell, 2020. https://doi.org/10.1016/j.cell.2020.04.042.
Miyasaka, M., Is BCG vaccination causally related to reduced COVID-19 mortality? EMBO Mol Med, 2020. doi: 10.15252/emmm.202012661
Kitamura, H., et al., IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity, 2005. 23(5): p. 491-502.
Xu, J., et al., The ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Pleiotropic Roles in Cancer. Front Physiol, 2017. 8: p. 276.
Eguchi, S., et al., Understanding Angiotensin II Type 1 Receptor Signaling in Vascular Pathophysiology. Hypertension, 2018. 71(5): p. 804-810.
Vaduganathan, M., et al., Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med, 2020. 382(17): p. 1653-1659.
Grover, S.P. and N. Mackman, Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis. Arterioscler Thromb Vasc Biol, 2018. 38(4): p. 709-725.
Zhang, X., et al., Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB. Virology, 2007. 365(2): p. 324-35.
Thompson, B.T., R.C. Chambers, and K.D. Liu, Acute Respiratory Distress Syndrome. N Engl J Med, 2017. 377(19): p. 1904-1905.
Imai, Y., et al., Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 2005. 436(7047): p. 112-6.
Marshall, R.P., et al., Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med, 2002. 166(5): p. 646-50.
Imai, Y., et al., Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell, 2008. 133(2): p. 235-49.
Ibrahim, Y.F., et al., Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-kappaB/JNK: a possible role of P-glycoprotein. Inflammopharmacology, 2020. 28(1): p. 215-230.
Wu, C., et al., Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med, 2020. doi: 10.1001/jamainternmed.2020.0994